Subsequently, the released MPLA and AS16 peptide synergistically activate cDC1 and maintain its activity, triggering a persistent antitumor immune response and effectively inhibiting tumor growth, metastasis, and recurrence. This evidence concerns the gene MPPE1 and neoplasm.